How many drugs are losing patent protection in 2033?

Drug Landscape tracks 52 marketed drugs with at least one patent expiring in 2033, sourced from FDA Orange Book + USPTO Patent Public Search.

What is a patent cliff?

A patent cliff is the year a major branded drug loses primary patent protection, opening the market to generic or biosimilar entry. Originator revenue typically drops 30–80% within 24 months, depending on the drug class and the strength of secondary patents.

Are these forecasts accurate?

Patent expiry dates are deterministic — they're the listed expiry from the Orange Book or USPTO record. Generic / biosimilar entry timing depends on litigation outcomes, paragraph IV challenges, settlements, and exclusivity periods which can shift the practical "cliff" by months to years.

Last reviewed 2026-05-14 · How we verify

2033 Pharmaceutical Patent Cliff

52 marketed drugs with patents expiring in 2033, joined to sponsor + therapeutic area + drug class. Forward-looking forecast. Sourced from FDA Orange Book + USPTO Patent Public Search.

52 drugs 150 patents 12 therapeutic areas Forward-looking

By therapeutic area

Oncology (14)

2033-01-10 — Cortef · Generic (originally Merck/Upjohn) · Corticosteroid [EPC] · Method of Use
2033-01-10 — Cortifoam · Pfizer · Corticosteroid · Method of Use
2033-01-10 — Solu-Cortef · Pfizer · Corticosteroid · Method of Use
2033-06-04 — Xyosted (Autoinjector) · Endo · Androgen
2033-06-12 — Camptosar · Pfizer · Topoisomerase Inhibitor
2033-06-12 — Camptosar · Pfizer · Topoisomerase Inhibitor · Method of Use
2033-06-19 — Ultravate · Ranbaxy · ulobetasol propionate
2033-07-01 — Gemzar · Accord Hlthcare · Nucleoside metabolic inhibitor · Formulation
2033-07-09 — Cometriq · Exelixis · Kinase Inhibitor
2033-08-23 — Sandimmune · Novartis · Calcineurin Inhibitor Immunosuppressant [EPC]
2033-09-06 — Venclexta · AbbVie · BCL-2 Inhibitor [EPC]
2033-09-30 — Taxotere · Sanofi · Microtubule Inhibitor [EPC] · Formulation
2033-10-18 — Viekira Pak (Copackaged) · AbbVie · Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor
2033-10-18 — Mektovi · Pfizer

Metabolic (12)

2033-03-06 — Tradjenta · Boehringer Ingelheim · Dipeptidyl Peptidase 4 Inhibitor [EPC]
2033-03-07 — Zavesca · AstraZeneca · Glucosylceramide Synthase Inhibitor [EPC] · Method of Use
2033-03-15 — Ozempic · Novo Nordisk · GLP-1 Receptor Agonist [EPC]
2033-04-02 — Unasyn · Pfizer · beta Lactamase Inhibitor
2033-04-07 — Tygacil · Pfizer · Tetracycline
2033-05-16 — Cuvposa · Shionogi · Anticholinergic
2033-05-16 — Glycopyrrolate · Yonsei University · Formulation
2033-05-31 — Tricor (Micronized) · Salix · Peroxisome Proliferator Receptor alpha Agonist [EPC] · Formulation
2033-08-01 — Ibsrela · Ardelyx Inc
2033-10-06 — TORSEMIDE · Loop Diuretic [EPC] · Formulation
2033-10-24 — DEXTROAMPHETAMINE · Central nervous system stimulant · Formulation
2033-12-24 — Relyvrio · Amylyx

Neuroscience (8)

2033-02-27 — Tegretol · Novartis AG (originally Geigy) · Mood Stabilizer [EPC] · Formulation
2033-03-15 — Renacidin · Baxter · Anti-coagulant
2033-03-19 — Topamax · Janssen · Formulation
2033-04-05 — Risperdal · Johnson & Johnson (Janssen) · Atypical Antipsychotic [EPC] · Formulation
2033-04-23 — Abilify · Generic (originally Otsuka/BMS) · Third-generation antipsychotic (D2 partial agonist) · Formulation
2033-07-01 — Duramorph Pf · Pfizer · Opioid Agonist · Formulation
2033-10-21 — Inbrija · Merz · Aromatic Amino Acid [EPC] · Method of Use
2033-10-23 — Phenergan Vc W/ Codeine · ANI Pharmaceuticals · Nonsteroidal Anti-inflammatory Drug [EPC]

Immunology (7)

2033-01-02 — Norgesic · Endo · centrally acting muscle relaxant with anticholinergic properties
2033-02-15 — Biktarvy · Gilead Sciences · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
2033-03-31 — Mobic · Boehringer Ingelheim · Nonsteroidal Anti-inflammatory Drug [EPC] · Formulation
2033-04-09 — Cupric Sulfate · Abraxis Pharm · copper sulfate · Formulation
2033-05-03 — Lotemax · Bausch Health · Corticosteroid · Formulation
2033-06-01 — Prevnar 20 · Pfizer Inc. · Pneumococcal conjugate vaccine · Composition of matter
2033-08-23 — Sandimmune · Novartis AG (originally Sandoz) · Calcineurin inhibitor (immunosuppressant) · Formulation

Respiratory (2)

2033-02-27 — Trikafta (Copackaged) · Vertex Pharms Inc
2033-07-15 — Symdeko (Copackaged) · Vertex Pharms

Infectious Disease (2)

2033-04-02 — Xacduro (Copackaged) · Entasis Therap · beta Lactamase Inhibitor
2033-04-07 — Tygacil · Fresenius Kabi · Tetracycline-class Antibacterial [EPC]

Pain (2)

2033-04-09 — Arnicare Leg Cramps · Sebela Womens Hlth · Copper-containing Intrauterine Device [EPC] · Formulation
2033-07-01 — MS Contin · Generic (multiple manufacturers) · Opioid analgesic · Formulation

Dermatology (1)

2033-03-15 — Prismasol Bk 0/3.5 In Plastic Container · lactic acid

Ophthalmology (1)

2033-09-10 — Miralax · Braintree · Osmotic Laxative [EPC]

Other (1)

2033-09-10 — Sodium Chloride · Pfizer · sodium chloride

Bone (1)

2033-10-06 — Jadelle · Fdn Consumer · Progestin · Compound

Nephrology (1)

2033-10-24 — Xelstrym · UCB · Central Nervous System Stimulant [EPC]

Subscribe to patent-cliff alerts

Push every new patent expiry into your RSS reader:

Biosimilar tracker — who's competing for each post-cliff originator
Patent cliff revenue calculator
2033 patent expiries dataset (CSV / JSON)